Startseite Kongressberichte & Archiv 24th Congress of EHA Novel strategies in multiple myeloma

Novel strategies in multiple myeloma

Henrik Gregersen, Valdas Peceliunas, Kari Remes, Fredrik Schjesvold, et al.

CARFILZOMIB AND DEXAMETHASONE MAINTENANCE PROLONG TIME TO PROGRESSION FOLLOWING SALVAGE ASCT IN MULTIPLE MYELOMA: A RANDOMIZED PHASE 2 TRIAL BY THE NORDIC MYELOMA STUDY GROUP

Conclusion:  Maintenance therapy with carfilzomib and dexamethasone maintenance prolongs median time to progression with approximately 6 months following salvage ASCT in multiple myeloma.

 

Sagar Lonial, Niels W.C.J. van de Donk, Rakesh Popat, Jeffrey A. Zonder, et al.

FIRST CLINICAL (PHASE 1B/2A) STUDY OF IBERDOMIDE (CC-220; IBER), A CELMOD, IN COMBINATION WITH DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Conclusion: IBER + DEX showed favorable efficacy and safety in heavily pretreated patients with RRMM who failed multiple prior therapies. This study is ongoing, including combinations of IBER with DARA or BORT.

 

James Abraham Malala, Glenn Willson Ng, Lucille Osias, Catherine Rosales

EFFECTIVENESS OF DENOSUMAB COMPARED TO ZOLEDRONIC ACID IN BONE DISEASE TREATMENT OF MULTIPLE MYELOMA (MM): A META-ANALYSIS

Conclusion: Our analysis still supports the use of zoledronic acid as a first line bone-targeted agent for MBD based on longer time to first SRE & lesser rates of the most common & dreaded complications such as hypocalcemia and jaw osteonecrosis, respectively. In addition, since denosumab doesn’t require renal function for use, our findings suggest that denosumab is an effective second-line agent for patients who has contraindications with zoledronic acid use due to renal dysfunction. Lastly, treatment of myeloma bone disease whichever agent doesn’t change the overall survival of multiple myeloma patients.

 

Paul G. Richardson, Albert Oriol, Alessandra Larocca, Paula Rodriguez Otero, et al.

HORIZON (OP-106): UPDATED EFFICACY AND SAFETY OF MELFLUFEN IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO DARATUMUMAB (DARA) AND/OR POMALIDOMIDE (POM)

Conclusion: Melflufen continues to have promising activity in pts with late-stage RRMM refractory to dara and/or pom and was generally well tolerated, with infrequent nonhematologic AEs and low rates of discontinuation due to AEs. 

 

Cristina Gasparetto, Suzanne Lentzsch, Gary Schiller, Natalie Callander, et al.

SAFETY AND EFFICACY OF COMBINATION OF SELINEXOR, DARATUMUMAB, AND DEXAMETHASONE (SDD) IN PATIENTS WITH MULTIPLE MYELOMA (MM) PREVIOUSLY EXPOSED TO PROTEASOME INHIBITORS AND IMMUNOMODULATORY DRUGS

Conclusion: Selinexor 100 mg QW can be combined safely with dara (per approved dosing) and dex to produce a deep and durable response warranting further investigation in pts with relapsed refractory MM. The ORR was 77% in pts who had not received prior dara or selinexor. Enrollment in the expansion arm is expected to be completed in March 2019 and full study results will be presented.